Bala, no lies. Changing endpoints after realizing the primary had utterly failed and design by switching to external control kills the integrity of the trial. The results weren't even put out until this JA was published. Why? Because they had to explain this tainted trial. SMFH. You can keep repeating your 70 person journal article till you die, it still doesn't change the fact that this trial can't be an approvable pivotal design. I'm going on record as saying rejection with recommendation of additional data/trials needed. Just wait for the decision and you will see who is the liar. Until then you can continue with the name calling if that makes you feel better about yourself.
Market Data 
Markets 
AI
